EMA to go extra mile to facilitate joint safety study for valproate

Feb 13 2015

• By Vibha Sharma

Listen to this article

In the course of its mandate to help companies carry out joint post-authorization safety studies under the EU pharmacovigilance legislation, the European Medicines Agency is planning to organize a teleconference/webinar for a new study concerning the anti-epileptic drug valproate so that interested companies may be introduced to each other and have the opportunity to interact and raise questions.

In the course of its mandate to help companies carry out joint post-authorization safety studies under the EU pharmacovigilance legislation, the European Medicines Agency is planning to organize a teleconference/webinar for a new study concerning the anti-epileptic drug valproate so that interested companies may be introduced to each other and have the opportunity to interact and raise questions.

The EMA has already ordered several PASS under the pharmacovigilance legislation and has taken steps to ensure these studies are...

More from Archive

Test-Pharma Warming Up To Benefits Of Australia’s Teletrials Initiative
Sep 24 2024
• By Sabbah
Test
Final Chance To Have Your Say: Take Our Reader Survey This Week
Sep 16 2024
• By Nielsen Hobbs
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Test H1 Heading
Sep 10 2024
Test H1 Story
Shape Our Content: Take The Reader Survey
Sep 04 2024
• By Nielsen Hobbs
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

More from Pink Sheet

Test FDA Voucher Program Approvals Will Come From Product Centers, But Ambiguity Lingers
Jan 23 2026
• By Sue Sutter
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
COVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’
Jan 05 2026
• By Sue Sutter
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
Nancy Tests New Podcast Template
Dec 16 2025
• By Derrick Gingery
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.